Cost Effective Supplement

Condition

– Cost Effective Supplements

Mild Cognitive Impairment

Quick navigation

Mild Cognitive Impairment definition

Some forgetfulness can be a normal part of aging. However, some people have more memory problems than other people their age. This condition is called mild cognitive impairment, or MCI. People with MCI can take care of themselves and do their normal activities.

Supplements that help with Mild Cognitive Impairment

  • Alpha-GPC for Mild Cognitive Impairment

test
Moderately Positive

The results of this study suggest the clinical usefulness and tolerability of CA in the treatment of the cognitive symptoms of dementia disorders of the Alzheimer type.

  • Blueberry for Mild Cognitive Impairment

test
Slightly Positive

The findings of this preliminary study suggest that moderate-term blueberry supplementation can confer neurocognitive benefit and establish a basis for more comprehensive human trials to study preventive potential and neuronal mechanisms.

  • CDP-choline for Mild Cognitive Impairment

test
Slightly Positive

We concluded that this molecule is suitable for the treatment of memory deficits in old people.

  • Curcumin for Mild Cognitive Impairment

test
Slightly Positive

  • DHEA for Mild Cognitive Impairment

test
Slightly Positive

The results of this double-blind, randomized trial do not support the hypothesis that hormone replacement with DHEA and/or atamestane might improve the course of frailty.
test
Slightly Positive

DHEA supplementation in older women with cognitive impairment may have beneficial effects on cognitive function and ADL.

  • Eleuthero for Mild Cognitive Impairment

test
Slightly Positive

In conclusion, E. senticosus safely improves some aspects of mental health and social functioning after 4 weeks of therapy, although these differences attenuate with continued use.

  • Fish Oil for Mild Cognitive Impairment

test
Slightly Positive

Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging.
test
Slightly Positive

Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function.

  • Ginkgo biloba for Mild Cognitive Impairment

test
Moderately Positive

EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.
test
Moderately Positive

GBT tablet can improve the therapeutic efficacy as well improve cognitive ability and cerebral blood flow supply of patients with VCIND.
test
Moderately Positive

EGb 761® improved cognitive functioning, neuropsychiatric symptoms and functional abilities in both types of dementia.
test
Moderately Positive

These exploratory findings helped to develop three hypotheses that will have to be proven in further studies: (1) there is no significant difference in the efficiency between EGb 761(R) and donepezil, (2) a combination therapy will be superior to a mono-therapy with one of both substances and (3) there will be less side effects under a combination therapy than under mono-therapy with donepezil.
test
Moderately Positive

In conclusion, treatment with EGb 761(®) at a once-daily dose of 240 mg was safe and resulted in a significant and clinically relevant improvement in cognition, psychopathology, functional measures and quality of life of patients and caregivers.
test
Moderately Positive

Compared with placebo, the use of G. biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.
test
Moderately Positive

The data add further evidence on the safety and efficacy of EGb 761 in the treatment of cognitive and non-cognitive symptoms of dementia.
test
Moderately Positive

Long-term use of standardised ginkgo biloba extract in this trial did not reduce the risk of progression to Alzheimer's disease compared with placebo.
test
Moderately Positive

The frequency of therapy responders in the two treatment groups differed significantly in favor of EGb 761, with p < 0.005 in Fisher's Exact Test. The intent-to-treat analysis of 205 patients led to similar efficacy results. Thus, the clinical efficacy of the ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type and multi-infarct dementia was confirmed. The investigational drug was found to be well tolerated.
test
Moderately Positive

No differences in the number of (gastrointestinal) side effects were observed between placebo and verum groups. These results indicate that the use of Ginkgo extracts in elderly individuals with cognitive impairment might be promising. Further research using both subjective and objective measurements is recommended.

  • Oxiracetam for Mild Cognitive Impairment

test
Slightly Positive

A significantly (p < 0.01) different effect in favour of oxiracetam was observed on the quality of life scale, and confirmed by significant (defined according to the Bonferroni technique) differences in some neuropsychological tests (e.g. controlled associations, short story). Four patients in the oxiracetam group complained of a total of 5 unwanted effects, and 1 on placebo complained of 3 unwanted effects, but none of them was withdrawn from the study.
test
Slightly Positive

Subjects were 34 MID patients and 39 PDD patients who met entrance criteria for the study. A repeated measures ANOVA showed significant improvement in both patients with MID and patients with PDD for word fluency. The total score on the Relatives' Assessment of Global Symptomatology-Elderly showed significant improvement for patients with PDD. The average score on the Instrumental Activities of Daily Living Scale, however, showed a significant decline for patients with PDD.
test
Slightly Positive

Based on improvement in global evaluations of clinical change, our analysis suggests that the drug may be of some benefit in MID.
test
Slightly Positive

Thirty-one patients on oxiracetam and 27 on placebo complained of a total of 35 and 32 minor unwanted effects, respectively. No clinically or statistically significant changes were observed on routine laboratory examinations.

  • Ginseng for Mild Cognitive Impairment

test
Slightly Positive

KRG showed good efficacy for the treatment of Alzheimer's disease; however, further studies with larger samples of patients and a longer efficacy trial should be conducted to confirm the efficacy of KRG.

  • Phenylpiracetam for Mild Cognitive Impairment

test
Slightly Positive

Patients exhibited higher mobility and daily activity, along with lower discomfort, anxiety and depression. EEG study showed more intensive alpha- and beta-rhythms, a decrease of paroxysmal activity and slow waves as well as a general tendency to its normalization.

  • PS for Mild Cognitive Impairment

test
Slightly Positive

The improvement carried over to the following wash-out and treatment phases. There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency. 16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group. BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level.
test
Slightly Positive

Patients were treated for 12 weeks with a formulation of bovine cortex phosphatidylserine (BC-PS; 100 mg t.i.d.) or placebo, and those treated with the drug improved on several cognitive measures relative to those administered placebo. Differences between treatment groups were most apparent among patients with less severe cognitive impairment. Results suggest that phosphatidylserine may be a promising candidate for study in the early stages of AD.
test
Slightly Positive

In conclusion, Soy-PS used in this study is considered as safety food ingredient and 6 months of Soy-PS supplementation could improve the memory functions of the elderly with memory complaints.
test
Slightly Positive

In conclusion, a daily supplement of S-PS does not affect memory or other cognitive functions in older individuals with memory complaints.

  • Piracetam for Mild Cognitive Impairment

test
Moderately Positive

Fifty Patients completed the investigation (25 piracetam, 25 placebo). There were no significant statistical differences between the two groups of patients on all measures utilized except for the Clinical Global Evaluation, where 52% of the patients on piracetam showed minimal improvement versus 25% of the placebo group (P less than 0.05).
test
Moderately Positive

The results of the meta-analysis demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.
test
Moderately Positive

A total of 135 patients, 45 in each group, completed the study. Combined therapy was most effective in patients whose baseline performance on memory tests was lowest. The best results were observed with 4.8 g of piracetam, especially when training sessions began after 6 weeks of drug treatment. This result was confirmed by the global impression of the principal investigator.
test
Moderately Positive

Thirty subjects completed the 1-year study. No improvement occurred in either group, but our results support the hypothesis that long-term administration of high doses of piracetam might slow the progression of cognitive deterioration in patients with AD. The most significant differences concerned the recall of pictures series and recent incident and remote memory. The drug was well-tolerated.
test
Moderately Positive

The effect of piracetam therapy with different dosages was studied in a double blind trial against placebo on its effect in psychoorganic syndrome of old age. 78 patients (61 females, 17 males) on the average of 73.2 years, showed statistically significant differences between piracetam therapy at a dosage of 3 X 1600 mg per day und placebo after a six week peroral therapy while no statistically significant differences between piracetam therapy at a dosage of 3X800 mg per day and placebo were found.

  • Yuan Zhi for Mild Cognitive Impairment

test
Slightly Positive

In conclusion, BT-11 could enhance some cognitive functions including memory in the elderly humans and therefore may be used as nutraceuticals that provide health benefits, including disease prevention and/or treatment.

  • Polypodium leucotomos for Mild Cognitive Impairment

test
Slightly Positive

The present results show that anapsos (360 mg/day) improves cognitive performance, cerebral blood perfusion and brain bioelectrical activity in patients with senile dementia. These effects of anapsos were more marked in demented patients with mild mental deterioration and/or with dementia of the Alzheimer type.

  • Vinpocetine for Mild Cognitive Impairment

test
Slightly Positive

The data analysis of the first 1011 individual medical records revealed the significant decrease of patient's complaints (p<0,001) and severity of neurological symptoms (p<0,05) as well as the improvement in scores on the Tinnetti scale (p<0,001) and the MMSE (p<0,001). The safety profile of the drug was confirmed.
test
Slightly Positive

Patients performed better on the Isaac speech activity test. The higher performance on the task and less errors were seen in the proof test that reflected the increase of attention/concentration. Patients showed the significant improvement on a scale that assessed self-rated health, activity and mood. The emotional state was normalized in 50% of patients during the treatment with vinpotropile. No adverse effects were observed.

  • Lion's Mane for Mild Cognitive Impairment

test
Slightly Positive

The Yamabushitake group's scores increased with the duration of intake, but at week 4 after the termination of the 16 weeks intake, the scores decreased significantly. Laboratory tests showed no adverse effect of Yamabushitake. The results obtained in this study suggest that Yamabushitake is effective in improving mild cognitive impairment.

Supplements that may help with Mild Cognitive Impairment when combined

Green Tea Extract
Theanine
Theanine
Green Tea Extract

What functions are affected by

What body systems are affected by

Scroll to top